Study of Acetazolamide With Temozolomide in Adults With Newly Diagnosed or Recurrent Malignant Glioma
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This is a Phase I study that examines the rate of dose limiting side effects in patients with
malignant astrocytoma treated with combination acetazolamide (ACZ) and temozolomide (TMZ).
Eligible patients must have histologically proven newly diagnosed, O6-methylguanine-DNA
methyltransferase (MGMT) methylated WHO grade III or IV astrocytoma and be planning to
undergo treatment with standard adjuvant TMZ (after completing treatment with TMZ and
ionizing radiation (IR)).
During this study, patients will receive daily oral ACZ with TMZ. During each cycle, ACZ will
be started on the day of TMZ initiation and continued for a total of 21 days.